Miles De Blasio
@milesdeblasio.bsky.social
Diabetes and Cardiometabolic researcher. Head of Cardio-Metabolic Physiology (CMP) Lab, Monash University.
Excited to share our new review in @natrevcardiol.nature.com with @rebeccahritchie.bsky.social on Inflammation in diabetic cardiomyopathy. We describe the inflammatory signalling pathways involved and discuss strategies that could potentially target these. rdcu.be/e9cE2 lnkd.in/gck-Qs8P
Inflammatory signalling in diabetic cardiomyopathy: molecular mechanisms and potential therapeutic strategies
Nature Reviews Cardiology - In this Review, De Blasio and Ritchie describe the inflammatory pathways involved in the pathogenesis of diabetic cardiomyopathy and discuss potential strategies to...
rdcu.be
Australia’s MRFF is sitting on billions of taxpayers’ dollars which was meant to be invested in world-leading, lifesaving health innovations.
Incredible lineup at #CSANZ2025! Holly Voges on stem cell heart valves, Nathan Palpant on genetic heterogeneity, Simon Foster on fibrosis targets, @milesdeblasio.bsky.social on gene therapy, and Sonia Shah on health inequities. Exciting breakthroughs!
Huge thank you to our amazing panellists for such thoughtful and inspiring conversations at today’s ECI Luncheon session 🙌 Over 50 attendees joined us to hear about the real pros & cons of doing an overseas postdoc #CSANZ2025 @fzmarques.bsky.social @dr-yktham.bsky.social @milesdeblasio.bsky.social
An honour to hear Professor Bryan Williams deliver the #CSANZ2025 RT Hall Lecture. 🌟 One of the world’s leading authorities on hypertension and cardiovascular medicine, Professor Williams shared fascinating insights into targeting aldosterone to prevent and treat CVD. 🫀
🌟 Thanks to everyone who joined our ECI Networking Event! We loved seeing such vibrant discussions on career development and research, led by the brilliant @fzmarques.bsky.social, @milesdeblasio.bsky.social and Rebecca Ritchie. Here’s to more collaboration and connection! 💬🔬 #CSANZ2025
Studies in mice reveal that AMPK activation mediates the effects of GLP-1RAs on AD, highlighting the therapeutic potential of GLP-1RAs for the treatment of #Alzheimers disease @nataging.nature.com www.nature.com/articles/s43...
Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice - Nature Aging
Zhang et al. identify GLP-1 receptor agonists mitigating Alzheimer’s disease-related cognitive decline and amyloid pathology in a transgenic mouse model via promoting phagocytosis and through activati...
nature.com
Great progress being made to understand mechanisms contributing to #HFpEF Fantastic talks from @rebeccahritchie.bsky.social & others at the #ishr2025 meeting in Nara #cardiosky @davorpavlovic.bsky.social @monikagladka.bsky.social @jmccardiology.bsky.social @jmccplus.bsky.social
SURMOUNT-5 Among participants with #obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72 www.nejm.org/doi/full/10....
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | NEJM
Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 di...
nejm.org